Search Results 71-80 of 9817 for N-Acetyl Selank

  1. Drugs and Supplements that Start with X - Mayo Clinic

    Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “X” to learn about drug side effects, proper use and ...

  2. Neurology - Clinical trials - Mayo Clinic

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  3. Neurology - Clinical trials - Mayo Clinic

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  4. A Study To Evaluate The Safety Of Lixivaptan In Subjects Previously Treated With Tolvaptan For Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    Herbert L; Chalasani N. Naga; Davern T. Timothy; Serrano J. Jose; Rochon J. James; . . Drug safety. 2009. ; 32(1):55-68. Drug-induced liver injury (DILI) is ...

  5. Publications - Aaron S. Mansfield, M.D. - Mayo Clinic

    Singh A, Sridhar A, Poddar A, Dimou A, Parikh K, Shanshal M, Schwecke A, Moffett N, Patel MR, Mansfield AS, Leventakos K. Combination of Lurbinectedin and ...

  6. Clinical trials - Oncology (Medical)

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  7. Neurosurgery - Clinical trials

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  8. Neurosurgery - Clinical trials

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  9. Clinical trials - Oncology (Medical)

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  10. A Study Of Seladelpar In Subjects With Primary Biliary Cholangitis (PBC) And An Inadequate Response To Or An Intolerance To Ursodeoxycholic Acid (UDCA) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...